SCHEMBL22001829

SCHEMBL22001829

CCCCCC/C(=N\OC(C)O)C(=O)c1cc2ccc(Sc3ccccc3)cc2oc1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 8/20 0.40
▸ MAOA P21397 5/20 0.40
▸ ALDH1A1 P00352 5/20 0.38
▸ KDM4E B2RXH2 5/20 0.38
▸ HSD17B10 Q99714 2/20 0.38
▸ LMNA P02545 1/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ CYP2C19 P33261 2/20 0.37
▸ CNR1 P21554 1/20 0.37
▸ CNR2 P34972 1/20 0.37
▸ CYP1A2 P05177 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ HSD11B1 P28845 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22001538 0.90 MAOB (0.42) MAOBMAOAALDH1A1KDM4EHSD17B10
SCHEMBL22001553 0.88 MAOB (0.41) MAOBMAOAALDH1A1KDM4EHSD17B10
SCHEMBL22001536 0.83 CYP2C19 (0.56) MAOBMAOAALDH1A1KDM4EHSD17B10
SCHEMBL22001831 0.82 MEN1 (0.53) MAOBMAOAALDH1A1KDM4EHSD17B10
SCHEMBL22001546 0.82 MAOB (0.39) MAOBMAOAALDH1A1KDM4EHSD17B10
SCHEMBL22001539 0.77 MAOB (0.43) MAOBMAOAALDH1A1KDM4EHSD17B10
SCHEMBL22058878 0.76 MAOB (0.43) MAOBMAOAALDH1A1KDM4EHSD17B10
SCHEMBL22001552 0.71 HSD11B1 (0.43) MAOBALDH1A1KDM4EHSD17B10LMNA
SCHEMBL22001540 0.70 CYP2C19 (0.58) MAOBMAOAALDH1A1KDM4EHSD17B10
SCHEMBL24677611 0.70 CES2 (0.42) ALDH1A1LMNARAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11142511-B2 Coumarin oxime ester compounds, preparation and use thereof HUBEI GURUN TECHNOLOGY CO., LTD. (CN) 2021-10-12 — — US disclosed
EP-3660008-A1 COUMARIN OXIME ESTER COMPOUND AND PREPARATION AND USE THEREOF Hubei Gurun Technology Co., Ltd (CN) 2020-06-03 — — EP disclosed
US-20200148660-A1 COUMARIN OXIME ESTER COMPOUNDS, PREPARATION AND USE THEREOF HUBEI GURUN TECHNOLOGY CO. LTD (CN) 2020-05-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200148660-A1 COUMARIN OXIME ESTER COMPOUNDS, PREPARATION AND USE THEREOF CBR3, POR, CYP3A4 MAOB 660/4885MAOA 1167/4885ALDH1A1 457/4885
US-11142511-B2 Coumarin oxime ester compounds, preparation and use thereof CBR3, POR, CYP3A4 MAOB 660/4885MAOA 1167/4885ALDH1A1 457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback